TechMARK movers: Oxford Bio down after update
22nd Sep 2009 11:34
Shares in Oxford BioMedica dropped after interim results from a Phase III study of the gene therapy company's cancer vaccine TroVax did not show a 'significant' survival advantage compared to placebo in the total population. 'Although I am disappointed that the trial did not meet its primary endpoi
Read moreTechMARK movers: GB and Oxford Biomedica drop
13th Jul 2009 12:37
Identity management specialists GB Group was slightly lower despite saying that interim pre-tax profit was marginally ahead of the same period last year. Profit before taxation stood at £135,000 for the interim period to 13 July 2009 compared with £41,000 the same time a year earlier. Revenue for t
Read moreTechMARK movers: Alizyme chief exec steps down
6th Jul 2009 14:21
Alizyme has lost chief executive Tim McCarthy as part of the drug developer's reconstruction effort. Non-executive director Alan Goodman will take charge of the day to day affairs of the business after McCarthy stepped down with immediate effect. The US Food and Drug Administration (FDA) has clear
Read moreSmall caps round-up: Timestrip, Amerisur Resources, Alizyme...
6th Jul 2009 10:11
Time and temperature measurement technology group Timestrip has appointed Vygon as the main distributor for TimestripIV products in the UK and Ireland. Vygon is a leading supplier of single-use medical and surgical products, including intravenous access devices, to the NHS. "We are delighted to be
Read moreTechMARK movers: Phoenix IT rallies on results
1st Jun 2009 16:20
IT services company Phoenix IT Group soared Monday morning after a strong performance by its business continuity division drove revenue and profits higher. Profit before tax and on-recurring items in the year to 31 March 2009 rose to £24.9m (£15.6m after non-recurring items) from £21.9m (£15.5m af
Read moreOxford Bio boosted by trials update
1st Jun 2009 15:19
Shares in gene therapy company Oxford Biomedica surged after it presented updated analyses of its trials of its TroVax drug on colorectal and renal cancer to the annual meeting of the American Society of Clinical Oncology (ASCO). In all trials TroVax was well tolerated and there were no serious b
Read moreOxford Biomedica funded through to 2012
14th May 2009 15:36
Gene therapy company Oxford Biomedica said all patients treated thus far in its Phase I/II trial of ProSavin, its Parkinson's disease treatment, have shown an encouragement improvement in their motor functions. Current plans are to complete the trial in the second half of 2010 and thereafter advanc
Read moreTechMARK movers: Oxford BioMedica gains on update
14th May 2009 12:56
Shares in Oxford BioMedica are up after the gene therapy group said the new ocular collaboration with sanofi-aventis and the termination of the TroVax collaboration will have a significant positive effect on its financial results for the current year and on the medium-term outlook. Recognised reven
Read more